

**Claims:**

1. Use of a substance selected from Follicle Stimulating Hormone (FSH) and FSH variant for the preparation of a pharmaceutical composition for the treatment  
5 and/or the reduction of gamete chromosomal alterations in a male.
2. Use according to claim 1 wherein the gamete chromosomal alterations are numerical alterations.
- 10 3. Use according to claims 1 or 2 wherein the gamete numerical chromosomal alterations is spermatozoa diploidy.
4. Use according to any of the preceding claims wherein the gamete numerical chromosomal alterations is sexual chromosome disomy.
- 15 5. Use according to any of the preceding claims wherein the male is human.
6. Use according to any of the preceding claims wherein the substance is FSH.
- 20 7. Use according to any of the preceding claims wherein the substance is rFSH.
8. Use according to any of the preceding claims wherein the substance is administered on alternate days.
- 25 9. Use according to any of the preceding claims wherein the substance is administered at or about 75 to 300 IU/dose.
10. Use according to any of the preceding claims wherein the substance is administered at or about 150 IU/dose.
- 30 11. Use according to any of the preceding claims wherein the substance is rFSH and the human male is suffering from gamete aneuploidy.